摘要
目的探讨2型糖尿病(T2DM)患者同型半胱氨酸(Hcy)、糖化血红蛋白(HbAlc)、尿微量白蛋白(MAU)与肾脏微血管病变的关系。方法 216例T2DM患者分为合并微血管病变组95例,无微血管病变组121例,治疗后按糖化血红蛋白(HbAlc)控制水平又分别分为HbAlc<7.0%组、HbAlc>7.0%组,以46例健康体检者为对照组;分别测定空腹血糖(FPG)、HbAlc、Hcy、脂蛋白a(Lpa)、MAU和尿β2微球蛋白(β2-MG)。结果 T2DM合并微血管病变患者HbAlc、Hcy、MAU和尿β2-MG明显高于无微血管病变患者(P<0.05);T2DM合并微血管病变患者治疗后HbAlc>7.0%组Lpa、Hcy、MAU、尿β2-MG水平明显高于HbAlc<7.0%组(P<0.05)。结论联合检测HbAlc、Hcy、Lpa、MAU和尿β2-MG可以动态观察DM患者肾脏微血管病变程度;强化血糖控制,改善Hcy、Lpa代谢对延缓T2DM微血管病变具有重要的临床意义。
Objective To explore the relationship between Hcy, HbAlc, MAU in type 2 diabetes（T2DM） and microangiopathy of the kidney. Methods 216 subjects with T2DM were allocated into microangiopathy group （95 subjects） and group without microangiopathy （121-subjects）. Those subjects were divided into one group（HbAlc〈7.0%） and another group （HbAlc〉7.0%） according to the control of HbAlc after the treatment. The control group（46 subjects） was healthy people. Fasting blood - sugar level （FPG）, HbAlc, Hcy, A lipoprotein （Lpa）, MAU and β2--microglobulin（ β2--MG） were also assayed respectively. Results The levels of HbAlc, Hcy, Lpa, MAU and β2-MG in T2DM group were higher with varying degrees than control group（P〈0.05）. The levels of Hcy, Lpa, MAU and β2-MG in the group of T2DM with microangiopathy but HbAlc〉7.0% were significantly higher than the group of HbAlc〈7.0% after the treatment（P〈0.05）. The levels of Lpa and β2-MG in the group of T2DM without microangiopathy but HbAlc〉7.0% were significantly higher than the group of HbAlc〈7.0% after the treatment（P〈0.05）. Conclusion The combined determination of HbAlc, Hcy, Lpa, MAU and β2-MG could dynamically observe the kidney microangiopathy. Improved glycaemic control and improved Hcy or Lpa metabolism were very important for postponed the damage in mieroangiopathy of T2DM.
出处
《分子诊断与治疗杂志》
2011年第1期25-28,共4页
Journal of Molecular Diagnostics and Therapy
